OCT used to guide personalized anti-VEGF treatments for neovascular age-related macular degeneration patients saved the United States $9 billion.
In the observational cohort study, researchers tracked Medicare spending through CPT codes on intravitreal injections, retinal OCT imaging and anti-VEGF treatment-specific J codes.
Through a meta-analysis and survey data, the calculated the cost of using OCT imaging to guide anti-VEGF treatment was $0.8 billion from 2008 to 2015, while Medicare savings from fewer drug injections totaled $10.3 billion. The National Institutes of Health and National
Uncategorized